COMPLETED

Draw-10: A Weekly Blood Draw Study to Understand the Biological Variability of Plasma pTau-217

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational study that will serially collect 10 plasma samples over the course of 9 weeks from the same individuals to assess fluctuations in blood biomarker results.

Official Title

Draw-10: A Weekly Blood Draw Study to Understand the Biological Variability of Plasma pTau-217

Quick Facts

Study Start:2025-01-27

Study Completion:2025-11-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT06742944

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* able and wiling to provide informed consent * Aged 50-80 years old at the time of signing study consent; participants aged 50-59 years will be no more than 20% of the total study population * Has normal cognition or mild impairment at screening MoCA by a score of greater than or equal to 18; participants with a Montreal Cognitive Assessment (MoCA Test) score between 18-25 will be no more than 20% of the total study population * able and wiling to fully comply with study procedures defined in the protocol * Written and spoken fluency in English	* Plans to begin any new treatment or is having surgery during the 9-week draw timeframe * Currently enrolled in a clinical trial using an investigational drug

Inclusion Criteria

Exclusion Criteria

* able and wiling to provide informed consent
* Aged 50-80 years old at the time of signing study consent; participants aged 50-59 years will be no more than 20% of the total study population
* Has normal cognition or mild impairment at screening MoCA by a score of greater than or equal to 18; participants with a Montreal Cognitive Assessment (MoCA Test) score between 18-25 will be no more than 20% of the total study population
* able and wiling to fully comply with study procedures defined in the protocol
* Written and spoken fluency in English

* Plans to begin any new treatment or is having surgery during the 9-week draw timeframe
* Currently enrolled in a clinical trial using an investigational drug

Contacts and Locations

Principal Investigator

Jessica B Langbaum, PhD

PRINCIPAL_INVESTIGATOR

Banner Alzheimer's Institute

Study Locations (Sites)

Banner Alzheimer's Institute

Phoenix, Arizona, 85006

United States

Banner Alzheimer's Institute Tucson

Tucson, Arizona, 85718

United States

Collaborators and Investigators

Sponsor: Banner Health

Jessica B Langbaum, PhD, PRINCIPAL_INVESTIGATOR, Banner Alzheimer's Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-27

Study Completion Date2025-11-30

Study Record Updates

Study Start Date2025-01-27

Study Completion Date2025-11-30

Terms related to this study

Keywords Provided by Researchers

plasma pTau217

Additional Relevant MeSH Terms

Alzheimer Disease